SmithKline exercises right on HGSI's KGF-2

SmithKline (SBH; LSE:SB) exercised an option under its 1996 deal with Human Genome Sciences (HGSI) to receive co-development and co-promotion rights to HGSI's repifermin keratinocyte growth factor-2 (...